1.16%
17.79%
3.96%
16.72%
60.29%
101.42%
141.45%
AI Spotlight on ALNY
Company Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1).
In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH.Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial.Alnylam Pharmaceuticals, Inc.
has strategic collaborations with Regeneron Pharmaceuticals, Inc.to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics.It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc.
The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Market Data
| Last Price | 277.16 |
| Change Percentage | 1.16% |
| Open | 274.86 |
| Previous Close | 273.99 |
| Market Cap ( Millions) | 35748 |
| Volume | 561203 |
| Year High | 304.39 |
| Year Low | 141.98 |
| M A 50 | 249.21 |
| M A 200 | 233.2 |
Financial Ratios
| FCF Yield | 0.04% |
| Dividend Yield | 0.00% |
| ROE | 323.66% |
| Debt / Equity | 4023.70% |
| Net Debt / EBIDTA | -154.25% |
| Price To Book | 1101.56 |
| Price Earnings Ratio | -107.26 |
| Price To FCF | 2225.51 |
| Price To sales | 17.07 |
| EV / EBITDA | -274.65 |
News
- Jan -30 - Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results
- Jan -27 - New Strong Buy Stocks for January 27th
- Jan -23 - GILD vs. ALNY: Which Stock Is the Better Value Option?
- Jan -21 - Best Momentum Stocks to Buy for January 21st
- Jan -21 - Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year?
- Jan -21 - New Strong Buy Stocks for January 21st
- Jan -13 - ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals
- Jan -12 - Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals
- Jan -07 - Alnylam Pharmaceuticals: Commercialization And Early-Stage Studies Are Likely To Drive 2025
- Dec -25 - Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
- Dec -19 - 4 Biotech Stocks Most Wall Street Analysts Are Bullish About
- Dec -04 - What Makes Alnylam (ALNY) a New Buy Stock
- Nov -27 - Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference
- Nov -26 - FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
- Nov -25 - Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
- Nov -18 - ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
- Nov -17 - Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
- Nov -11 - Alnylam downgraded to Underperform from Peer Perform at Wolfe Research
- Nov -04 - Alnylam to Webcast Presentations at Upcoming November Investor Conferences
- Nov -01 - Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Ribonucleic Acid Interference Therapeutics
Expected Growth : 12.03 %
What the company do ?
Ribonucleic Acid Interference (RNAi) Therapeutics from Alnylam Pharmaceuticals, Inc. is a gene-silencing approach that uses small RNA molecules to selectively inhibit disease-causing genes.
Why we expect these perspectives ?
Alnylam's RNAi therapeutics growth is driven by increasing adoption of ONPATTRO for hATTR amyloidosis, strong pipeline progress, and partnerships with major pharma companies. The company's proprietary GalNAc-conjugate technology enables targeted delivery and enhanced efficacy, fueling growth. Additionally, the growing demand for innovative treatments in rare genetic diseases and Alnylam's leadership in RNAi research contribute to its 12.03% growth.
Alnylam Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| ONPATTRO | A RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) |
| GIVLAARI | A RNAi therapeutic for the treatment of acute hepatic porphyria (AHP) |
| OXLUMO | A RNAi therapeutic for the treatment of primary hyperoxaluria type 1 (PH1) |
| Leqvio | A RNAi therapeutic for the treatment of high cholesterol |
Alnylam Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
Alnylam Pharmaceuticals, Inc. has a low threat of substitutes due to its unique RNA interference (RNAi) technology, which provides a competitive advantage in the market.
Bargaining Power Of Customers
Alnylam Pharmaceuticals, Inc. has a medium bargaining power of customers due to the presence of a few large pharmaceutical companies and research institutions that purchase its products.
Bargaining Power Of Suppliers
Alnylam Pharmaceuticals, Inc. has a low bargaining power of suppliers due to its ability to manufacture its own products and reduce dependence on external suppliers.
Threat Of New Entrants
Alnylam Pharmaceuticals, Inc. has a high threat of new entrants due to the growing interest in RNAi technology and the potential for new companies to enter the market.
Intensity Of Rivalry
Alnylam Pharmaceuticals, Inc. operates in a moderately competitive market with a few established players, resulting in a medium intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 109.94% |
| Debt Cost | 4.45% |
| Equity Weight | -9.94% |
| Equity Cost | 5.98% |
| WACC | 4.30% |
| Leverage | -1105.64% |
Alnylam Pharmaceuticals, Inc. : Quality Control
Alnylam Pharmaceuticals, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IDYA | IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product … |
| TECH | Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, … |
| INSM | Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as … |
| BBIO | BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging … |
| KRYS | Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Bio-Techne
A-Score
1-Year Total Return ->
🥈
Insmed
A-Score
1-Year Total Return ->
🥉
Alnylam Pharmaceuticals
A-Score
1-Year Total Return ->
4
Krystal Biotech
A-Score
1-Year Total Return ->
5
BridgeBio Pharma
A-Score
1-Year Total Return ->
6
